 Lantern Pharma NASDAQ: LTRN, a clinical stage biotechnology company using its proprietary RADR artificial intelligence A.I. platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced its financial results for the second quarter ended June 30, 2020, and provided an update on its RD pipeline and other corporate developments. 